Drug Profile
Research programme: bispecific therapeutics - Ambrx/Zhejian Hisun Pharmaceuticals
Alternative Names: Bispecifics - AmbrxLatest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ambrx
- Developer Ambrx; Zhejiang Hisun Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer